Cargando…

Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign

Recently, the World Health Organization (WHO) approved RTS, S/AS01 (RTS, S) as the world's first malaria vaccine for partial malaria protection in young children at risk. While this immunization drive begins during the unprecedented pandemic of the SARS-CoV-2 Virus, the WHO has also approved 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Pritik A., Hasan, Mohammad Mehedi, Sahito, Abdul Moiz, Patel, Suyog Y., Ramproshad, Sarker, Mondal, Banani, Essar, Mohammad Yasir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212924/
https://www.ncbi.nlm.nih.gov/pubmed/35757307
http://dx.doi.org/10.1016/j.amsu.2022.104011
_version_ 1784730721817985024
author Shah, Pritik A.
Hasan, Mohammad Mehedi
Sahito, Abdul Moiz
Patel, Suyog Y.
Ramproshad, Sarker
Mondal, Banani
Essar, Mohammad Yasir
author_facet Shah, Pritik A.
Hasan, Mohammad Mehedi
Sahito, Abdul Moiz
Patel, Suyog Y.
Ramproshad, Sarker
Mondal, Banani
Essar, Mohammad Yasir
author_sort Shah, Pritik A.
collection PubMed
description Recently, the World Health Organization (WHO) approved RTS, S/AS01 (RTS, S) as the world's first malaria vaccine for partial malaria protection in young children at risk. While this immunization drive begins during the unprecedented pandemic of the SARS-CoV-2 Virus, the WHO has also approved 7 Vaccines in 2021 for the vaccination of children at risk. This article explores the quandary that would occur to the officials in charge of carrying out large vaccination campaigns against these two deadly infectious illnesses in several regions including the continent of Africa. The article also outlines the priorities for resolving this dilemma, offers evidence-based solutions, and provides a summary of recent significant events and their consequences. While providing the latest data, a discussion on the causation of the dilemma with clear recommendations for possible solutions has been explored as well.
format Online
Article
Text
id pubmed-9212924
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92129242022-06-22 Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign Shah, Pritik A. Hasan, Mohammad Mehedi Sahito, Abdul Moiz Patel, Suyog Y. Ramproshad, Sarker Mondal, Banani Essar, Mohammad Yasir Ann Med Surg (Lond) Short Communication Recently, the World Health Organization (WHO) approved RTS, S/AS01 (RTS, S) as the world's first malaria vaccine for partial malaria protection in young children at risk. While this immunization drive begins during the unprecedented pandemic of the SARS-CoV-2 Virus, the WHO has also approved 7 Vaccines in 2021 for the vaccination of children at risk. This article explores the quandary that would occur to the officials in charge of carrying out large vaccination campaigns against these two deadly infectious illnesses in several regions including the continent of Africa. The article also outlines the priorities for resolving this dilemma, offers evidence-based solutions, and provides a summary of recent significant events and their consequences. While providing the latest data, a discussion on the causation of the dilemma with clear recommendations for possible solutions has been explored as well. Elsevier 2022-06-18 /pmc/articles/PMC9212924/ /pubmed/35757307 http://dx.doi.org/10.1016/j.amsu.2022.104011 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Shah, Pritik A.
Hasan, Mohammad Mehedi
Sahito, Abdul Moiz
Patel, Suyog Y.
Ramproshad, Sarker
Mondal, Banani
Essar, Mohammad Yasir
Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign
title Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign
title_full Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign
title_fullStr Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign
title_full_unstemmed Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign
title_short Vaccine dilemma for children at risk: Recently approved malaria vaccine versus ongoing COVID-19 vaccination campaign
title_sort vaccine dilemma for children at risk: recently approved malaria vaccine versus ongoing covid-19 vaccination campaign
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212924/
https://www.ncbi.nlm.nih.gov/pubmed/35757307
http://dx.doi.org/10.1016/j.amsu.2022.104011
work_keys_str_mv AT shahpritika vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign
AT hasanmohammadmehedi vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign
AT sahitoabdulmoiz vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign
AT patelsuyogy vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign
AT ramproshadsarker vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign
AT mondalbanani vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign
AT essarmohammadyasir vaccinedilemmaforchildrenatriskrecentlyapprovedmalariavaccineversusongoingcovid19vaccinationcampaign